CLOSED
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and anal. Track Piramal Pharma Limited's live NSE:PPLPHARMA share price ₹198.52 (+1.81%), market cap ₹₹263B. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for PPLPHARMA — real-time NSE India stock intelligence.
Open
₹196.36
High
₹202.95
Low
₹193.03
Prev. Close
₹194.99
52W High
₹209.44
52W Low
₹132.30
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and anal
Key Takeaway
Piramal Pharma Limited is rated strong buy with a P/E of —x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is Piramal Pharma Limited fairly valued right now?
Because a P/E of —x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting Piramal Pharma Limited
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
2,270 Cr
Revenue
-69 Cr
Net Profit
0%
ROE
0%
ROCE
-2.37
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 7,032 | 8,106 | 9,061 | 8,759 | 9,096 |
| Net Profit | -186 | 18 | 91 | -326 | -296 |
| ROE (%) | — | — | — | 0.0% | 0.0% |
| EPS (₹) | — | — | — | -2.37 | -2.37 |
| Debt/Equity | — | — | — | 70.0 | 70.0 |